Chanticleer Holdings agreed to merge with Sonnet BioTherapeutics, a privately-held clinical-stage biopharmaceutical company developing innovative targeted biologic drugs, in a $6m deal. The aim of the merger is to advance a pipeline of novel immune therapeutics. “This merger is an exciting next step for Sonnet that complements Sonnet’s committed financing of up to $100 million and further supports our commitment to advancing our novel oncology product candidates with the ultimate goal of overcoming persistent challenges in cancer care. As we become a publicly-traded entity, we look forward to accelerating the execution of our proprietary platform technology for innovating immune therapeutics that includes our pipeline of clinical and pre-clinical therapeutic candidates,” Pankaj Mohan, Sonnet Founder and Chief Executive Officer.